MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/1545-5017.70448

Медицинская библиотека · Pediatric blood & cancer · 2026

SARS-CoV-2 Vaccination and Immune Thrombocytopenia in Children: A Multicenter Study.

Angela Guarina, Paola Giordano, Giuseppe Lassandro, Ugo Ramenghi, Paola Saracco, Loredana Farinasso, Sabrina Bombaci, Sofia Tasca, Dora Notarangelo Lucia, Chiara Gorio, Maurizio Miano, Erika Massaccesi, Barbara Bruschi, Irene D'Alba, Angelica Barone, Ilaria Fontanili, Giuseppe Palumbo, Gianluca Boscarol, Federico Verzegnassi, Simone Cesaro, Agnese Corbelli, Silverio Perrotta, Maddalena Casale, Francesca Rossi, Mariamaddalena Marrapodi, Antonio Ruggiero, Alberto Romano, Saverio Ladogana, Angela Maggio, Giovanna Russo, Piero Farruggia

СтатьяМногоцентровое исследованиеПеревод в очереди

Аннотация

BACKGROUND

Immune thrombocytopenia (ITP) is the most common acquired bleeding disorder in childhood. Although viral infections and some vaccinations are recognized triggers, data on the onset or exacerbation of ITP following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination in pediatric patients remain limited.

OBJECTIVES

To evaluate the incidence and clinical characteristics of new-onset ITP and the safety of SARS-CoV-2 vaccination in children with preexisting or resolved ITP.

METHODS

We evaluated the incidence and clinical characteristics of ITP occurring after SARS-CoV-2 vaccination, as well as the effects of vaccination in children with preexisting ITP.

RESULTS

De novo ITP: five cases of new-onset ITP were identified nationwide, most of which occurred after the first vaccine dose (80%). Despite low median platelet counts at presentation, no major or fatal bleeding events were observed. Most patients responded favorably to first-line treatments (intravenous immunoglobulins and/or corticosteroids), and 80% achieved normal platelet counts at the last follow-up. Preexisting ITP: among 164 vaccinated patients with complete clinical data, only 8.5% (n = 14) experienced a transient platelet count decline or new bleeding manifestations. Notably, no relapses occurred among the 34 patients who were in clinical remission at the time of vaccination.

CONCLUSIONS

ITP following SARS-CoV-2 vaccination in the pediatric population is exceedingly rare and generally mild. Moreover, SARS-CoV-2 vaccination appears safe in children with preexisting or resolved ITP.

Для цитирования: Angela Guarina, Paola Giordano, Giuseppe Lassandro, Ugo Ramenghi, Paola Saracco, Loredana Farinasso, Sabrina Bombaci, Sofia Tasca, Dora Notarangelo Lucia, Chiara Gorio, Maurizio Miano, Erika Massaccesi, Barbara Bruschi, Irene D'Alba, Angelica Barone, Ilaria Fontanili, Giuseppe Palumbo, Gianluca Boscarol, Federico Verzegnassi, Simone Cesaro, Agnese Corbelli, Silverio Perrotta, Maddalena Casale, Francesca Rossi, Mariamaddalena Marrapodi, Antonio Ruggiero, Alberto Romano, Saverio Ladogana, Angela Maggio, Giovanna Russo, Piero Farruggia. SARS-CoV-2 Vaccination and Immune Thrombocytopenia in Children: A Multicenter Study.. Pediatric blood & cancer. 2026. DOI: 10.1002/1545-5017.70448.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.